Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a San Diego-based clinical-stage biotechnology company that completed its public market debut through a business combination with First Light Acquisition Group, a blank-check company that conducted its IPO in 2021. The de-SPAC transaction closed in 2023, bringing Calidi's oncolytic virus-based cancer therapy platform to public markets. Calidi operates in the oncology and cell therapy sector, advancing treatments that use engineered stem cells to carry and amplify cancer-fighting viruses. The company's 10-K filing reflects its ongoing reporting obligations as a public registrant. To access the full filing history, sponsor details, and deal analytics for CLDI and the broader SPAC universe, create a free account on SpacDesk.